Cargando…

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

The large heterogeneity in response to immune checkpoint inhibitors is driving the exploration of predictive biomarkers to identify patients who will respond to such treatment. We extended our previously suggested modeling framework of atezolizumab pharmacokinetics, IL18, and tumor size (TS) dynamic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Netterberg, Ida, Bruno, René, Chen, Ya‐Chi, Winter, Helen, Li, Chi‐Chung, Jin, Jin Y., Friberg, Lena E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020300/ https://www.ncbi.nlm.nih.gov/pubmed/31991070 http://dx.doi.org/10.1002/psp4.12489

Ejemplares similares

A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
por: Netterberg, Ida, et al.
Publicado: (2018)

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
por: Chan, Phyllis, et al.
Publicado: (2021)

Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
por: Krishnan, Sreenath M., et al.
Publicado: (2021)

Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
por: Netterberg, Ida, et al.
Publicado: (2017)

Bayesian forecasting of tumor size metrics and overall survival
por: Krishnan, Sreenath M., et al.
Publicado: (2022)

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma
por: Tokunaga, Takayuki, et al.
Publicado: (2023)

External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
por: Kassir, Nastya, et al.
Publicado: (2023)

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
por: Shemesh, Colby S., et al.
Publicado: (2019)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
por: Morrissey, Kari M., et al.
Publicado: (2019)

Nomogram for predicting overall survival time of patients with stage IV colorectal cancer
por: Lv, Min-Yi, et al.
Publicado: (2022)

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
por: Wu, Benjamin, et al.
Publicado: (2021)

Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy
por: Kerioui, M., et al.
Publicado: (2021)

Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF
por: Harrold, John, et al.
Publicado: (2020)

Time-dependent endpoints as predictors of overall survival in multiple myeloma
por: Félix, Jorge, et al.
Publicado: (2013)

Application of Machine Learning for Tumor Growth Inhibition – Overall Survival Modeling Platform
por: Chan, Phyllis, et al.
Publicado: (2020)

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
por: Liu, Stephen V., et al.
Publicado: (2021)

Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival
por: Masubuchi, Ken, et al.
Publicado: (2022)

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
por: Hansson, E K, et al.
Publicado: (2013)

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
por: Nie, Wei, et al.
Publicado: (2021)

Overall Survival and Survival Time by Palliative Performance Scale: A Retrospective Cohort Study in Thailand
por: Vankun, Pimprapa, et al.
Publicado: (2022)

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
por: Peters, Solange, et al.
Publicado: (2021)

Quantifying the Time Course of Visual Object Processing Using ERPs: It's Time to Up the Game
por: Rousselet, Guillaume A., et al.
Publicado: (2011)

Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma
por: Ikeda, Munehiro, et al.
Publicado: (2022)

Machine Learning and Radiomic Features to Predict Overall Survival Time for Glioblastoma Patients
por: Chato, Lina, et al.
Publicado: (2021)

Time taken for a primary tumor to metastasize to the brain and the overall survival of patients with brain metastasis: An analysis of outcomes and factors affecting survival
por: Hao, Peiyu, et al.
Publicado: (2022)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer
por: Lee, Shu‐Hui, et al.
Publicado: (2019)

Survival Rates with Time Course of Frozen-thawed Pacific Oyster Larvae in Indoor Rearing System
por: Kim, Ki Tae, et al.
Publicado: (2013)

PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor
por: Schindler, E, et al.
Publicado: (2016)

Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
por: Unome, Shinji, et al.
Publicado: (2022)

Time Course of Odor Categorization Processing
por: Bae, Jisub, et al.
Publicado: (2021)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
por: Hayashi, Tsuguru, et al.
Publicado: (2020)

Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes
por: Endo, Yukinori, et al.
Publicado: (2023)

Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer
por: Sherrill, B, et al.
Publicado: (2008)

The impact of time factors on overall survival in patients with nasopharyngeal carcinoma: a population-based study
por: Chen, Po-Chun, et al.
Publicado: (2016)

Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis
por: Sun, Wenzheng, et al.
Publicado: (2018)

Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma
por: Chen, Viola J., et al.
Publicado: (2019)

Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study
por: Lansu, Jules, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vm93b0u2gl5fbo6vqpo96imtr6